Steven Prestrelski's Net Worth
$2.7 Million
Who is Steven Prestrelski?
Steven Prestrelski has an estimated net worth of $2.7 Million. This is based on reported shares across multiple companies, which include XERIS PHARMACEUTICALS INC, and Xeris Biopharma Holdings, Inc..
SEC CIK
Steven Prestrelski's CIK is 0001744027
Past Insider Trading and Trends
2021 was Steven Prestrelski's most active year for acquiring shares with 9 total transactions. Steven Prestrelski's most active month to acquire stocks was the month of September. 2021 was Steven Prestrelski's most active year for disposing of shares, totalling 11 transactions. Steven Prestrelski's most active month to dispose stocks was the month of September. 2018 saw Steven Prestrelski paying a total of $18,706.80 for 53,082 shares, this is the most they've acquired in one year. In 2018 Steven Prestrelski cashed out on 97,990 shares for a total of $248,737.56, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
XERIS PHARMACEUTICALS INC No price found
Chief Scientific OfficerSteven Prestrelski used to own units in Common Stock but no longer holds any shares there. In the year 2018 Steven Prestrelski filed a total of 17 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -494.78K |
—
|
—
|
0
|
Oct 5
| |||
Form 4
| -1.97% | -10.00K |
$4.07 | -$40,725.00 | 496.82K |
Scheduled
|
Apr 12
| ||
Form 4
| +24.58% | 100K |
—
|
—
| 506.82K |
Jan 29
| |||
Form 4
| -2.40% | -10.00K |
$6.01 | -$60,058.00 | 406.82K |
Scheduled
|
Jan 13
| ||
Form 4
| -2.34% | -10.00K |
$5.72 | -$57,244.00 | 416.82K |
Scheduled
|
Jan 11
| ||
Form 4
| -2.29% | -10.00K |
—
|
—
| 426.82K |
Dec 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 14
| |||
Form 4
| +3.56% | 15K |
—
|
—
| 436.82K |
Jan 31
| |||
Form 4
| -2.32% | -10.00K |
$5.50 | -$54,992.00 | 421.82K |
Scheduled
|
Jan 13
| ||
Form 4
| -3.89% | -17.50K |
—
|
—
| 431.82K |
Nov 19
| |||
Form 4
| -5.81% | -27.70K |
$12.01 | -$332,600.44 | 449.32K |
Scheduled
|
Jan 14 - Oct 11
| ||
Form 4
| -2.05% | -10.00K |
$9.56 | -$95,649.00 | 477.02K |
Scheduled
|
Apr 11
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 31
| |||
Form 4
| -0.47% | -2.30K |
—
|
—
| 487.02K |
Scheduled
|
Jan 11
| ||
Form 4
|
—
|
0
|
$8.51 | -$230,030.76 | 489.32K |
Dec 24 - Dec 26
| |||
Form 4
| +8.27% | 37.36K |
—
|
—
| 489.32K |
Jun 25
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Xeris Biopharma Holdings, Inc. (XERS) Snapshot price: $2.51
Chief Scientific OfficerSteven Prestrelski owns 719,780 units of Common Stock which is worth $1,806,647.80. In the year 2021 Steven Prestrelski filed a total of 5 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +26.33% | 150K |
—
|
—
| 719.78K |
Jan 31
| |||
Form 4
|
—
|
0
|
$1.56 | -$19,410.97 | 569.78K |
Scheduled
|
Feb 22
| ||
Form 4
| +15.16% | 75K |
—
|
—
| 569.78K |
Jan 3
| |||
Form 4
|
∞
| 494.78K |
—
|
—
| 494.78K |
Oct 5
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||